Xing C F, Pan X, Wang C, Ma L, Wang X L, Li Y J, He B
Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200030, China.
Zhonghua Xin Xue Guan Bing Za Zhi. 2023 Jul 24;51(7):742-749. doi: 10.3760/cma.j.cn112148-20230604-00327.
To explore the long-term clinical efficacy of transcatheter repair of mitral paravalvular leak (PVL) post surgical mitral valve replacement. This study is a retrospective study. Patients who completed transcatheter repair of paravalvular leak after surgical mitral valve replacement at Shanghai Chest Hospital, Shanghai Jiaotong University School of Medicine from March 2010 to December 2018 were included. Technical success was defined as the occluder being stably implanted in the paravalvular leak site without affecting the function of the mitral valve and surrounding tissues; and there were no intervention-related complications, such as new hemolysis or aggravated hemolysis, and echocardiography confirmed mitral paravalvular regurgitation reduced by more than 1 grade. Patients were followed up at 30 days, 1, and 3 years after the intervention. The main endpoints were all-cause death and re-surgery due to interventional failure or serious complications. The occurrence of occluder-mediated hemolysis and chronic renal insufficiency was recorded, and patients were monitored with echocardiography during follow up. A total of 75 patients were included, aged (54.3±22.9) years old, and 38 patients were males. All patients had decreased cardiac function and/or hemolysis before intervention. Procedural success was achieved in 54 patients (72.0%). Incidence of device-mediated hemolysis was 18.7% (14/75). During the follow-up period, all-cause death occurred in 7 patients (9.3%), and 3 were cardiac deaths.The 3-year event-free survival rate was 81.3% (61/75). The need for cardiac surgery was 9.3% (7/75): 3 cases due to severe device-mediated hemolysis, 2 cases due to prosthetic valve failure and 2 cases due to moderate to severe residual regurgitation. The echocardiography follow-up results showed that the position of the occluder was stable, there was no impact on the artificial valve function and surrounding structures, and the residual regurgitation was stable without progressive increase in event-free patients. Compared with pre-intervention, the left ventricular end systolic diameter ((33.9±7.4)mm vs. (38.3±8.9) mm, =0.036), end diastolic diameter ((53.7±8.3) mm vs. (58.4±9.1) mm, =0.045) and left atrial diameter (59.3 (44.5, 90.7) mm vs. 64.3 (44.8, 96.6) mm, =0.049) were significantly reduced, pulmonary artery systolic pressure was also significantly decreased ((36.5±15.8) mmHg vs. (46.3±14.9) mmHg, =0.022, 1 mmHg=0.133 kPa). There was no significant difference between 3 years and 1 year after transcatheter repair of mitral paravalvular leak post surgical mitral valve replacement (all >0.05). Transcatheter repair of mitral paravalvular leak post surgical mitral valve replacement is an effective treatment option in selective patients.
探讨经导管修复二尖瓣置换术后二尖瓣瓣周漏(PVL)的长期临床疗效。本研究为回顾性研究。纳入2010年3月至2018年12月在上海交通大学医学院附属上海胸科医院完成二尖瓣置换术后经导管修复瓣周漏的患者。技术成功定义为封堵器稳定植入瓣周漏部位,不影响二尖瓣及周围组织功能;且无干预相关并发症,如新发溶血或溶血加重,超声心动图证实二尖瓣瓣周反流降低超过1级。干预后30天、1年和3年对患者进行随访。主要终点为全因死亡以及因介入失败或严重并发症而再次手术。记录封堵器介导的溶血和慢性肾功能不全的发生情况,随访期间用超声心动图对患者进行监测。共纳入75例患者,年龄(54.3±22.9)岁,男性38例。所有患者干预前均有心脏功能下降和/或溶血。54例(72.0%)手术成功。封堵器介导的溶血发生率为18.7%(14/75)。随访期间,7例(9.3%)患者全因死亡,其中3例为心源性死亡。3年无事件生存率为81.3%(61/75)。心脏手术需求为9.3%(7/75):3例因严重封堵器介导的溶血,2例因人工瓣膜功能障碍,2例因中重度残余反流。超声心动图随访结果显示,封堵器位置稳定,对人工瓣膜功能及周围结构无影响,无事件患者残余反流稳定,无进行性增加。与干预前相比,左心室收缩末期内径((33.9±7.4)mm对(38.3±8.9)mm,P=0.036)、舒张末期内径((53.7±8.3)mm对(58.4±9.1)mm,P=0.045)和左心房内径(59.3(44.5,90.7)mm对64.3(44.8,96.6)mm,P=0.049)均显著减小,肺动脉收缩压也显著降低((36.5±15.8)mmHg对(46.3±14.9)mmHg,P=0.022,1mmHg = 0.133kPa)。二尖瓣置换术后经导管修复二尖瓣瓣周漏3年与1年的结果无显著差异(均P>0.05)。二尖瓣置换术后经导管修复二尖瓣瓣周漏对部分患者是一种有效的治疗选择。